| Literature DB >> 31493013 |
Lina Varzaityte1, Raimondas Kubilius2, Lolita Rapoliene3, Ruta Bartuseviciute4, Arvydas Balcius4, Kestutis Ramanauskas5, Irena Nedzelskiene6.
Abstract
The treatment of OA using pharmaceutical and non-pharmaceutical measures remains a topical subject. The purpose of this study is to assess the effect of natural factors (mineral water and mud) on changes in the functional state of patients with knee joint OA. Ninety-two adult people with grade I-III knee joint OA according to the Kellgren and Lawrence scoring system participated in the study. The subjects received 10 mineral water bath plus physical therapy or mud application procedures plus physical therapy or physical therapy alone every other day. The effectiveness of the treatment was assessed on the basis of anthropometric changes of data, VAS, SF-36, KOOS questionnaire indicators. Significantly greater walking speed, test of 5 sit downs/stand ups, circumference of a knee joint, flexion and extension range, flexor and extensor strength after treatment lasting 1 month were obtained in the intervention group. After 1 month after treatment pain intensity scores over the past month and when changing position were significantly higher in the control group. The positive changes in SF-36 were identified after 1 month after treatment: physical activity increased and pain decreased in the intervention groups. There was no significant difference between the averages of any KOOS subscale in groups. However, average percentages of symptoms, stiffness, and pain in the intervention groups were significantly better after treatment and lasting 1 month after treatment. Balneotherapy and peloid therapy effectively reduce pain and improve the functional state of patients with OA of a knee joint.Entities:
Keywords: Balneotherapy; Knee joint osteoarthritis; Peloid therapy; Rehabilitation
Mesh:
Year: 2019 PMID: 31493013 PMCID: PMC7266807 DOI: 10.1007/s00484-019-01785-z
Source DB: PubMed Journal: Int J Biometeorol ISSN: 0020-7128 Impact factor: 3.787
Fig. 1Trial organization scheme
The baseline characteristics of subjects (age, sex, body mass index), with respect to groups of subjects
| Characteristic | All groups | Group I | Group II | Group III | |
|---|---|---|---|---|---|
| Age, A (SD) | 64.6 (11.4) | 65.0 (10.8) | 61.0 (13.4) | 67.9 (8.9) | |
| Sex (%) | |||||
| Men | 13.0 | 21.9 | 10.0 | 6.7 | |
| Women | 87.0 | 78.1 | 90.0 | 93.3 | |
| Body mass index, A (SD) kg/m2 | 29.4 (4.3) | 29.3 (3.9) | 29.2 (4.6) | 29.8 (4.6) |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; A, average; SD, standard deviation; χ2, chi-square criteria; p, level of significance.
Distribution of change in clinical parameters after treatment (stages I–II), with respect to groups of subjects
| Variable | Group I ( | Group II ( | Group III ( | |
|---|---|---|---|---|
| Walking speed, A (SD), m/s | 0.20 (0.25)a | 0.19 (0.28)b | − 0.24 (0.24)a,b | |
| 5 sit downs/stand ups, A (SD), s | 3.83 (3.02)a | 4.24 (3.79)b | 1.98 (2.00)a,b | |
| Left leg | ||||
| Thigh circumference, A (SD), cm | 0.78 (1.38) | 0.50 (1.46) | 0.76 (1.73) | |
| Knee circumference, A (SD), cm | 1.42 (2.80) | 1.40 (2.22) | 0.96 (1.94) | |
| Calf circumference, A (SD), cm | 1.16 (1.17) | 1.15 (1.29) | 0.66 (1.50) | |
| Flexion range, A (SD), degrees | 16.2 (9.3)a | 16.8 (14.3)b | 5.4 (5.1)a,b | |
| Extension range, A (SD), degrees | 1.92 (3.62) | 1.0 (2.38)b | 1.87 (2.17)b | |
| Flexor strength, A (SD), score | 1.12 (0.44)a | 1.04 (0.81)b | 0a,b | |
| Extensor strength, A (SD), score | 1.20 (0.76)a | 1.25 (0.85)b | 0.07 (0.25)a,b | |
| Right leg | ||||
| Thigh circumference, A (SD), cm | 1.23 (1.75) | 1.28 (1.80) | 0.73 (2.16) | |
| Knee circumference, A (SD), cm | 1.24 (1.40)a | 1.12 (0.98)b | 0.18 (1.58)a,b | |
| Calf circumference, A (SD), cm | 1.22 (2.51) | 1.10 (1.1) | 0.35 (1.29) | |
| Flexion range, A (SD), degrees | 19.0 (13.3)a | 17.2 (12.9)b | 5.10 (6.40)a,b | |
| Extension range, A (SD), degrees | 2.12 (7.14) | 1.88 (3.79) | 2.0 (2.33) | |
| Flexor strength, A (SD), score | 1.17 (0.48)a | 1.08 (0.40)b | 0a,b | |
| Extensor strength, A (SD), score | 1.00 (0.80)a | 1.13 (0.63)b | 0.07 (0.25)a,b | |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; A, average; SD, standard deviation; F, by Fisher test; χ2, by Kruskal–Wallis test
a,bp < 0.05
Distribution of change of subjects’ clinical parameters after 1 month after treatment (stages I–III), with respect to groups of subjects
| Variable | Group I ( | Group II ( | Group III ( | |
|---|---|---|---|---|
| Walking speed, A (SD), m/s | 0.28 (0.27)a | 0.24 (0.25)b | − 0.20 (0.18)a,b | |
| 5 sit downs/stand ups, A (SD), s | 5.40 (3.41)a | 5.61 (3.72)b | 2.10 (2.61)a,b | |
| Left leg | ||||
| Thigh circumference, A (SD), cm | 1.38 (2.09) | 1.02 (1.89) | 0.78 (1.77) | |
| Knee circumference, A (SD), cm | 2.0 (2.33) | 1.67 (2.53) | 1.11 (1.58) | |
| Calf circumference, A (SD), cm | 1.14 (1.50) | 1.87 (2.50) | 0.74 (1.55) | |
| Flexion range, A (SD) degrees | 19.9 (10.8)a | 18.8 (17.5)b | 4.20 (5.50)a,b | |
| Extension range, A (SD), degrees | 2.36 (4.56) | 0.83 (2.50) | 1.77 (2.22) | |
| Flexor strength, A (SD), score | 1.28 (0.54)a | 1.22 (0.85)b | 0a,b | |
| Extensor strength, A (SD), score | 1.36 (0.91)a | 1.30 (0.97)b | 0.07 (0.25)a,b | χ2 = 39.506, a,b |
| Right leg | ||||
| Thigh circumference, A (SD), cm | 1.67 (1.96) | 1.69 (2.09) | 0.91 (2.13) | |
| Knee circumference, A (SD), cm | 1.80 (1.65)a | 1.52 (1.53)b | 0.33 (1.74)a,b | |
| Calf circumference, A (SD), cm | 1.34 (2.29) | 1.50 (1.81) | 0.36 (1.20) | |
| Flexion range, A (SD), degrees | 22.6 (15.9)a | 18.8 (15.4)b | 1.13 (8.89)a,b | |
| Extension range, A (SD), degrees | 2.28 (7.59) | 2.33 (4.46) | 1.87 (2.97) | |
| Flexor strength, A (SD), score | 1.24 (0.72)a | 1.13 (0.54)b | 0a,b | |
| Extensor strength, A (SD), score | 1.20 (0.96)a | 1.23 (0.92)b | 0.07 (0.25)a,b | |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; A, average; SD, standard deviation; F, by Fisher test; χ2, by Kruskal–Wallis test
a,bp < 0.05
Distribution of the scores of subjects’ pain intensity questionnaire before, after treatment, and after 1 month after treatment (I, II, III stage), with respect to groups of subjects
| Group I ( | Group II ( | Group III ( | ||
|---|---|---|---|---|
| A (SD), score | ||||
| Over the past month | ||||
| Stage I | 5.88 (1.66) | 6.33 (2.34) | 5.67 (2.51) | |
| Stage II | 4.44 (1.93) | 4.57 (2.47) | 5.27 (2.75) | |
| Stage III | 3.63 (2.04)a | 4.38 (2.44) | 5.13 (2.66)a | |
| During daytime | ||||
| Stage I | 5.97 (1.91) | 6.27 (2.10) | 4.93 (2.52) | |
| Stage II | 4.03 (2.10) | 4.40 (2.34) | 4.57 (2.74) | |
| Stage III | 3.25 (2.08) | 4.48 (2.61) | 4.57 (2.64) | |
| During night time | ||||
| Stage I | 4.16 (2.60) | 4.37 (3.18) | 3.37 (3.58) | |
| Stage II | 2.81 (2.16) | 3.07 (2.57) | 3.13 (3.69) | |
| Stage III | 2.34 (1.98) | 2.55 (2.38) | 3.0 (3.73) | |
| When moving | ||||
| Stage I | 6.69 (2.07) | 7.17 (2.10) | 5.73 (2.48) | |
| Stage II | 4.81 (2.15) | 5.33 (2.59) | 5.40 (2.63) | |
| Stage III | 4.25 (2.53) | 4.72 (2.52) | 5.20 (2.46) | |
| When changing position | ||||
| Stage I | 6.69 (2.49) | 6.90 (2.35) | 6.03 (2.48) | |
| Stage II | 4.66 (2.07) | 5.0 (2.69) | 5.90 (2.85) | |
| Stage III | 4.06 (2.50)a | 4.55 (2.60) | 5.77 (2.89)a | |
| At rest | ||||
| Stage I | 3.47 (2.36) | 3.40 (2.43) | 3.03 (3.10) | |
| Stage II | 2.28 (2.28) | 2.77 (2.34) | 2.87 (3.32) | |
| Stage III | 1.50 (1.74) | 1.83 (1.58) | 2.93 (3.27) | |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; A, average; SD, standard deviation; F, by Fisher test; χ2, by Kruskal–Wallis test.
a,bp < 0.05
Distribution of the scores of separate areas of SF-36 questionnaire before, after treatment, and 1 month after treatment (stages I, II, III), with respect to groups of subjects
| Group I ( | Group II ( | Group III ( | ||
|---|---|---|---|---|
| A (SD), score | ||||
| Physical activity | ||||
| Stage I | 40.2 (20.3) | 43.4 (18.4) | 39.5 (16.7) | |
| Stage II | 54.3 (23.5) | 52.0 (16.2) | 43.7 (16.2) | |
| Stage III | 53.5 (25.1) | 55.0 (17.2) | 45.3 (16.3) | |
| Restriction of activity due to physical problems | ||||
| Stage I | 43.0 (41.8) | 59.2 (41.3) | 54.3 (42.8) | |
| Stage II | 68.3 (35.3) | 75.9 (32.4) | 61.2 (38.1) | |
| Stage III | 68.0 (37.7) | 72.4 (34.9) | 60.0 (38.1) | |
| Pain | ||||
| Stage I | 58.7 (19.3) | 52.5 (16.8) | 58.5 (16.5) | |
| Stage II | 43.4 (18.2) | 42.8 (16.5) | 54.4 (19.9) | |
| Stage III | 43.4 (21.3) | 39.8 (17.2) | 51.5 (22.7) | |
| Overall health assessment | ||||
| Stage I | 55.8 (15.7) | 52.5 (11.4) | 50.7 (15.7) | |
| Stage II | 51.2 (12.4) | 51.2 (12.4) | 49.3 (16.1) | |
| Stage III | 52.1 (13.3) | 46.7 (12.1) | 52.7 (16.2) | |
| Energy levels/vitality | ||||
| Stage I | 34.8 (6.4) | 32.2 (8.3) | 34.3 (11.4) | |
| Stage II | 35.8 (7.4) | 32.8 (8.4) | 33.8 (10.8) | |
| Stage III | 35.8 (6.0) | 33.6 (7.9) | 33.5 (10.5) | |
| Social function | ||||
| Stage I | 41.5 (7.7) | 41.9 (8.6) | 41.5 (13.4) | χ2 = 0.478, |
| Stage II | 42.7 (8.7) | 42.5 (6.0) | 41.5 (13.4) | |
| Stage III | 42.2 (9.4) | 41.4 (8.3) | 43.7 (14.6) | |
| Restriction of activity due to emotional disorders | ||||
| Stage I | 72.9 (39.2) | 75.6 (36.0) | 74.7 (34.1) | |
| Stage II | 86.2 (30.5) | 78.2 (34.8) | 78.2 (32.5) | |
| Stage III | 83.3 (33.1) | 82.8 (32.9) | 75.6 (34.9) | |
| Emotional state | ||||
| Stage I | 38.1 (5.5) | 38.3 (7.4) | 38.0 (7.8) | |
| Stage II | 41.7 (7.3) | 39.8 (8.3) | 38.8 (8.7) | |
| Stage III | 40.9 (5.7) | 37.5 (7.7) | 40.1 (9.1) | |
Group I, provided with bath procedures; group II, provided with mud procedures; A, average; SD, standard deviation; F, by Fisher test; χ2, by Kruskal–Wallis test
Distribution of data of KOOS questionnaire on the knee (before, after treatment, and after 1 month after treatment (stages I, II, III), with respect to groups of subjects
| Subscales of KOOS questionnaire | Group I ( | Group II ( | Group III ( | |
|---|---|---|---|---|
| A (SD), score | ||||
| Symptoms | ||||
| Stage I | 51.9 (15.1) | 50.5 (13.0) | 51.2 (17.7) | |
| Stage II | 66.3 (15.3)a | 61.5 (16.3) | 53.9 (20.7)a | |
| Stage III | 67.2 (15.0)a | 64.9 (16.8) | 53.9 (20.7)a | |
| Stiffness | ||||
| Stage I | 55.4 (16.3) | 53.8 (13.4) | 49.1 (19.8) | |
| Stage II | 67.2 (13.9)a | 64.5 (17.4)b | 53.4 (21.6)a,b | |
| Stage III | 70.4 (15.3)a | 69.0 (16.5)b | 53.6 (21.7)a,b | |
| Pain | ||||
| Stage I | 53.1 (15.7) | 48.3 (12.5) | 47.1 (15.4) | |
| Stage II | 65.3 (16.4)a | 60.3 (18.3) | 51.0 (19.1)a | |
| Stage III | 65.2 (14.8)a | 62.2 (18.1) | 52.3 (19.8)a | |
| Mobility, everyday life | ||||
| Stage I | 28.8 (17.8) | 25.5 (15.8) | 35.2 (21.5) | |
| Stage II | 40.6 (22.3) | 42.0 (21.4) | 39.8 (23.2) | |
| Stage III | 42.8 (21.2) | 41.8 (21.8) | 40.2 (21.6) | |
| Mobility, sports and recreational activities | ||||
| Stage I | 34.9 (16.6) | 35.2 (20.6) | 36.3 (15.8) | |
| Stage II | 44.3 (23.7) | 46.1 (21.6) | 39.2 (16.8) | |
| Stage III | 50.2 (22.4) | 50.0 (22.2) | 41.3 (18.1) | |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; A, average; SD, standard deviation; F, by Fisher test; χ2, by Kruskal–Wallis test
a,bp < 0.05
Distribution of ROC test predicted values of changes of variables of clinical trials and changes of their characteristics after treatment and 1 month after treatment, according to groups of subjects
| Associated criterion | AUC [95% CI], % | Sensitivity/specificity [95% CI], % | Group III/group I+II, | Group III OR [95% CI] |
|---|---|---|---|---|
| Walking speed after treatment ≤ 0.025 m/s | 94,8 [85.4–97.1] | 93.3 [77.9–99.2] 87.1 [76.1–94.3] | 28 (93.3) 8 (12.9) | 94.5 [18.789–475.285] |
| Walking speed 1 months after treatment ≤ 0.05 m/s | 97.8 [92.4–99.8] | 93.3 [77.9–99.2] 96.7 [88.7–99.6] | 28 (93.3) 2 (3.3) | 413.0 [55.287–3085.16] |
| 5 sit downs/stand ups after treatment ≤ 1.92, s | 72.3 [61.9–81.2] | 69.0 [49.2–84.7] 77.4[65.0–87.1] | 20 (69.0) 14 (22.6) | 7.619 [2.841–20.434] |
| 5 sit downs/stand 1 month after treatment ≤ 2.75 s | 81.1 [71.5–88.6] | 65.5 [45.7–82.1] 86.9 [75.8–94.2] | 19 (65.5) 8 (13.1) | 12.587 [4.33–36.596] |
| Left leg | ||||
| Flexion range after treatment ≤ 4.0° | 82.0 [71.8–89.8] | 56.7 [37.4–74.5] 91.8 [80.4–97.7] | 17 (56.7) 4 (8.2) | 14.712 [4.207–51.445] |
| Flexion range 1 month after treatment ≤ 5° | 87.4 [77.9–93.8] | 70.0 [50.6–85.3] 83.3 [69.8–92.5] | 21 (70.0) 8 (16.7) | 11.667 [3.926–34.666] |
| Right leg | ||||
| Flexion range after treatment ≤ 10.0° | 82.7 [72.6–90.2] | 90.0 [73.5–97.9] 60.0 [45.2–73.6] | 27 (90.0) 20(40.0) | 13.5 [3.606–50.545] |
| Flexion range 1 month after treatment ≤ 12.0° | 88.0 [78.8–94.2] | 93.3 [77.9–99.2] 63.3 [48.3–76.6] | 28 (93.3) 18 (36.7) | 24.111 [5.13–113.333] |
| Left leg | ||||
| Flexor strength after treatment ≤ 0 score | 93.9 [86.1–98.0] | 100 [88.4–100] 89.8 [77.8–96.6] | 30 (100) 5 (10.2) | – |
| Flexor strength 1 month after treatment ≤ 0 score | 93.8 [85.9–98.0] | 100 [88.4–100] 87.5 [74.8–95.3] | 30 (100) 6 (12.5) | – |
| Right leg | ||||
| Flexor strength after treatment ≤ 0 score | 98.0 [91.9–99.8] | 100 [88.4–100] 95.9 [86.0–99.5] | 30 (100) 2 (4.1) | – |
| Flexor strength 1 month after treatment ≤ .0 score | 94.9 [87.5–98.6] | 100 [88.4–100] 89.8 [77.8–96.6] | 30 (100) 5 (10.2) | – |
| Left leg | ||||
| Extensor strength after treatment ≤ 0 score | 90.5 [81.8–95.9] | 93.3 [77.9–99.2] 85.7 [72.8–94.1] | 28 (23.3) 7 (14.3) | 84.0 [16.252–434.166] |
| Extensor strength 1 month after treatment ≤ 0 score | 89.5 [80.5–95.3] | 93.3 [77.9–99.2] 83.3 [69.8–92.5] | 28 (93.3) 8 (16.7) | 70.0 [13.811–354.781] |
| Right leg | ||||
| Extensor strength after treatment ≤ 0 score | 89.7 [80.6–95.5] | 93.3 [77.9–99.2] 87.0 [73.7–95.1] | 28 (93.3) 6 (13.0) | 93.333 [17.542–496.59] |
| Extensor strength 1 month after treatment ≤ .0 score | 87.0 [77.4–93.6] | 93.3 [77.9–99.2] 78.7 [64.3–89.3] | 28 (93.3) 10 (21.) | 51.8 [10.505–255.437] |
Group I, provided with bath procedures; group II, provided with mud procedures; group III, control; OR, odds ratio; CI, confidence interval; AUC, area under the ROC curve
Distribution of ROC test predicted values of KOOS questionnaire’s on the knee changes of variables and changes of their characteristics after treatment and 1 month after treatment, according to groups of subjects
| Associated criterion, score | AUC [95% CI], % | Sensitivity/specificity [95% CI], % | Group III/group I+II, | Group III OR [95% CI] |
|---|---|---|---|---|
| Symptoms after treatment ≤ 1.5 | 83.7 [74.5–92.8] | 86.7 [79.7–93.6] 80.6 [72.6–88.7] | 26 (86.7) 12 (19.4) | 27.083 [7.942–92.363] |
| Symptoms 1 month after treatment ≤ 1.0 | 82.0 [72.7–91.4] | 86.7 [79.7–93.6] 77.4 [68.9–86.0] | 26 (86.7) 14 (22.6) | 22.286 [6.65–74.686] |
| Stiffness after treatment ≤ 5.5 | 76.4 [66.2–86.6] | 86.7 [79.7–93.6] 66.1 [56.5–75.8] | 26 (86.7) 21 (33.9) | 12.69 [3.912–41.165] |
| Stiffness 1 month after treatment ≤ 5.5 | 82.8 [73.6–92.1] | 86.7 [79.7–93.6] 79.0 [70.7–87.4] | 26 (86.7) 13 (21.0) | 24.5 [7.252–82.769] |
| Pain after treatment ≤ 1.5 | 82.8 [73.6–92.1] | 86.7 [79.7–93.6] 79.0 [70.7–87.4] | 26 (86.7) 13 (21.0) | 24.5 [7.252–82.769] |
| Pain 1 month after treatment ≤ 1.5 | 76.3 [65.7–86.9] | 80.0 [71.8–88.2] 72.6 [63.5–81.7] | 24 (80.0) 17 (27.4) | 10.588 [3.689–30.389] |
| Mobility, everyday life after treatment ≤ 13.5 | 71.6 [60.8–82.3] | 86.7 [79.7–93.6] 56.5 [46.3–66.6] | 26 (86.7) 27 (43.5) | 8.426 [2.625–27.047] |
| Mobility, everyday life 1 month after treatment ≤ 24.5 | 76.2 [65.5–87.0] | 76.7 [68.0–85.3] 75.8 [67.1–84.6] | 23 (76.7) 15 (24.2) | 10.295 [3.688–28.736] |
| Mobility, sports and recreational activities after treatment ≤ 3.0 | 76.4 [66.2–86.6] | 86.7 [79.7–93.6] 66.1 [79.7–93.6] | 26 (86.7) 21 (33.9) | 12.69 [3.912–41.165] |
| Mobility, sports and recreational activities 1 month after treatment ≤ 3.0 | 79.5 [69.3–89.7] | 86.7 [79.7–93.6] 79.0 [70.7–87.4] | 24 (80.0) 13 (21.0) | 15.077 [5.102–44.557] |